RxDoctor Payments Data

Osama Elshazly, MD

Internal Medicine · Panama City, FLNPI 1407822877

Payments from drug & device makers

$723in general payments, 2019–2025

Across 40 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$160
  • AstraZeneca$119
  • Exact Sciences$90
  • GSK$81
  • Lilly USA, LLC$49
  • Boehringer Ingelheim$46
  • plus $177 from 8 others

What the payments were for

  • Food & beverage$723100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$723 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$43,683
Medicare patients
135
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$58,355
JanuviaSitagliptin Phosphate42$40,393
MounjaroTirzepatide27$28,626
OzempicSemaglutide21$24,596
Nurtec OdtRimegepant Sulfate11$20,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,439
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$13,203
Combivent RespimatIpratropium/Albuterol Sulfate14$10,538
EntrestoSacubitril/Valsartan11$10,458
Tresiba Flextouch U-100Insulin Degludec13$7,608
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,065
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl54$5,751
Gabapentin105$2,615
Ventolin HfaAlbuterol Sulfate37$2,491
Albuterol Sulfate HfaAlbuterol Sulfate58$2,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$18$79,19182 claims
Lilly USA, LLCMounjaro$49$28,62627 claims
GSKTrelegy Ellipta, Anoro Ellipta$81$26,50438 claims
Novo NordiskOzempic$39$24,59621 claims
AstraZenecaBreztri Aerosphere$119$13,20318 claims
Boehringer IngelheimCombivent Respimat$46$10,53814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →